Refining Value

Health economist writing about HEOR/market access, drug development, biopharma

[Refining Value @RefiningValue]

Bluesky has seen a surge lately and increasingly feels like the old Twitter while this place increasingly feels broken

[Zach Brennan @ZacharyBrennan]

There's now 10 Humira biosimilars on the US market priced at 80+% off the brand name version (and 7 at 85+% off)

...and $ABBV still controls 77% of the market...

[Refining Value @RefiningValue]

@BertrandBio @biobrainbox Agree. Pricing unlikely to change w inc PoS. I think risk for Eur (generalizing) is as US-Eur opportunity diff increases, the oft-higher Eur evidence reqs will increasingly not be worth it, especially when it comes to Ph3. Eur will be forced to lower bar or forego access@ margin

[Bertrand Delsuc @BertrandBio]

Nice slide from $BMY on Medicare Part D redesign - valid for all the BigP but impact dpding on overall exposure to this market segment

[Refining Value @RefiningValue]

@Sports_bios @bradloncar On "malignant competition" it has always been there, no? You just have cheaper options for inlicensing now, improving the economics rather than worsening. To me that is the one trend acting against everything else you mentioned. Still an uphill battle

[Jack Scannell @JackScannell13]

Interesting comment on GLP-1s in Parkinsons: “’We should know by now that it’s extremely rare that a drug just happens to treat a disease, if not designed for it”. And obvious reply is that we do know failure is extremely common for diseases that a drug IS designed for it. 1/n

[Melinda French Gates @melindagates]

Today I am thinking of the people I’ve met around the world—children, parents, health workers, teachers—who will be harmed by the Trump administration’s decision to try to dismantle USAID and walk back U.S. leadership in global health and poverty reduction.

I’m thinking, too, about the dangerous ripple effects this will cause. In an increasingly interconnected world, we’re all better off when lifesaving medicines are developed and delivered, when disease outbreaks are halted, and when nations lift themselves out of poverty.

Strong leaders throughout history have understood that foreign aid builds a heathier, safer, more prosperous world—and that’s a goal everyone should be able to get behind.

[Refining Value @RefiningValue]

@Biohazard3737 Is the bulk of the societal value the industry produces in the hiring it does or the drugs it discovers? If societal value is the aim then why does it matter where discovery etc happen? A good amount of development spend will happen in the US anyway given the site-driven costs

[Refining Value @RefiningValue]

@varma_ashwin97 @Frank_S_David PCSK9i trials even worse (larger n, longer follow up, and an argument that OO and FOURIER didn't show the full benefit because f/u wasn't long enough). $NVS ORION-4 will also be worse than Entresto CVOT

[Refining Value @RefiningValue]

In other words, executive branch is meant to get checked and balanced, arguably here. Of course no "right" answer for a given issue including this one.

[Refining Value @RefiningValue]

I think it's a fair take but Senate was also partly created for and has a long history of blunting large and sudden swings driven by popular opinion. Can argue to do what the founders intended of it (and thereby government as a whole) Senate has a responsibility to not confirm

[Brad Loncar @bradloncar]

My take on RFK Jr is that while a disagree with many of his ideas and I think he has a questionable temperament, I do think he should be confirmed because in his case he was essentially part of the ticket and many Americans in part voted for him and for change in healthcare.

[Refining Value @RefiningValue]

Some interesting parallels re Deepseek: US-based LLMs and the bio explosion in China:US biotech

Still feel it'll be net positive for the industries and consumers at large in both cases

[EU Medicines Agency @EMA_News]

We have moved...

We have decided to take a break from X, but we want to keep talking about medicines and public & animal health with all of our followers.

Find us on Bluesky ➡️ https://t.co/Vec4pn4TdE

[Refining Value @RefiningValue]

I shouldn't try to apply logic here and apologies for the rare political post but if NIH is developing all of the drugs then why are we freezing all of the funding again?

[Refining Value @RefiningValue]

Looking forward to this. Love the premise and can't think of anyone better for it

[BiotechTV @BiotechTV]

𝐍𝐞𝐰 𝐒𝐡𝐨𝐰 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with @gline.

Matt will share his perspective on news, and interview other biotech leaders.

Visit the show's dedicated page: https://t.co/QmH9QszoP2

[Refining Value @RefiningValue]

Interesting that Leerink now has a team doing independent cost effectiveness analyses. Seems to be taking more of a GCEA approach. An alternative to ICER?

https://t.co/dKbeVvPfNf

[Refining Value @RefiningValue]

@matthewherper @michael_gilman @afinley @DShaywitz Would've been up there with Sanofi paying to get out of aflibercept eye development inherited from Aventis..

[Refining Value @RefiningValue]

Prior post on the dementia "effect" studies here https://t.co/GIXgiAOYWK

[Refining Value @RefiningValue]

Been saying this with all of the GLP RWE. Good hypothesis generation for sure but let's not forget how hard it is to measure / adjust for confounding in these data pts w GLP-1 access fundamentally different - higher SES, education etc

[Alex Harding @AlexHarding7]

I feel like I shouldn’t have to say this…

Association is not causation. This is a retrospective study with obvious potential confounders.

It would have been nice to see a dose response (not shown in article) or a before/after initiation of GLP1 analysis (also not shown).

[Refining Value @RefiningValue]

Laudable goal to improve trial data collection efficiency but I'm not sure how it is diff than existing alts and ultimately faces same ? of whether it's actually replacing any trial collection/cost or just adding on.

But it's Abernathy so worth paying attn to. 🤞something here

[Matthew Herper @matthewherper]

Amy Abernethy, former No. 2 at FDA, outlines new company’s plans to streamline clinical research https://t.co/E1phyAUE3w